Geron (NASDAQ:GERN) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Geron (NASDAQ:GERN) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05, Briefing.com reports. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The firm had revenue of $28.27 million for the quarter, compared to the consensus estimate of $18.97 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The business’s quarterly revenue was up 17138.4% compared to the same quarter last year.

Geron Price Performance

Shares of GERN traded down $0.04 during mid-day trading on Friday, reaching $4.25. The company had a trading volume of 12,134,583 shares, compared to its average volume of 10,462,797. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60. The company’s 50-day moving average is $4.32 and its 200-day moving average is $4.30. The company has a market capitalization of $2.56 billion, a P/E ratio of -13.28 and a beta of 0.52.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Geron in a research note on Friday, August 9th. HC Wainwright assumed coverage on Geron in a research note on Tuesday. They issued a “buy” rating and a $8.00 target price on the stock. StockNews.com upgraded Geron to a “sell” rating in a research note on Monday, August 5th. Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Geron in a research note on Thursday, August 8th. Finally, Scotiabank assumed coverage on Geron in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.05.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.